CytoNiche Launches 3D FloTrix Experience Center in Singapore to Advance Affordable Stem Cell Therapies
Singapore, 22 July, 2025 – CytoNiche Biotech, a pioneer in 3D cell mass production technology, officially launched its 3D FloTrix Experience Center in Singapore. The achievement represents an important milestone in the firm’s expansion plan around the world, presenting the technology used in China’s first-approved stem cell therapy, with estimated costs by the company as only a fraction of similar Western treatments.
Cutting the High Cost of Stem Cell Therapies
The exorbitant price of stem cell therapies is a universal limitation. For instance, stem cell therapy is priced at $1.55 million per treatment available on the market, whereas China’s approved stem cell injection, approved in 2025, is about 158,400 CNY (~$21,600) per course (source: company annual report). CytoNiche’s 3D FloTrix™ platform facilitates this reduction in costs by way of GMP-grade dissolvable microcarriers and a clinically validated automated 3D cell manufacturing system, backing the world’s first commercially scaled 3D-manufactured stem cell therapy.
Singapore: A Hub for Global Expansion
The 3D FloTrix™ Experience Center is both a global partnership headquarters, a technology exhibit, and a regional training center, driving cost-effective stem cell production adoption. “Singapore’s strong biotech ecosystem and clear regulatory climate are perfect for launch,” stated Dr. Yan Xiaojun, Chief Technology Officer. “We seek to expand access to cell therapies via more advanced 3D culture systems.”
CytoNiche’s Scientific Journey and Milestones
Chief Scientist Professor Du Yanan at the launch looked back at CytoNiche’s 2018 beginnings to facilitating China’s very first approved stem cell therapy: “Twenty years ago, I studied in Singapore.”. Currently, we come back with a solution to revolutionize global cell therapy production.” The ceremony at 1:18 p.m. included a ribbon-cutting ceremony by Professor Du Yanan, Dr. Liu Wei, and Dr. Yan Xiaojun, followed by a symbolic “Ong Lai” pineapple tossing for good fortune. CytoNiche entered into four cooperation agreements with South Korean, Thai, Indian, and Malaysian companies to distribute 3D FloTrix™ technology and consumables.
Looking Ahead: Global Accessibility in Cell Therapy
CytoNiche aims to increase its international client base and reduce cell therapy prices via automated biomanufacturing platforms. “This is not merely opening a center—it’s a step toward ensuring regenerative medicine becomes accessible worldwide,” stated Professor Du.
About CytoNiche Biotech
CytoNiche Biotech, established in 2018, provides 3D cell mass production systems. Its 3D FloTrix™ platform facilitates cell therapy expansion, harvesting, and processing using GMP-grade dissolvable microcarriers, serum-free media, and automated bioreactors. More at: https://en.cytoniche.com.
Media Contact
Organization: CytoNiche Biotech Pte. Ltd.
Contact Person: Sun Yuan
Website: https://www.cytoniche.com/
Email: Send Email
Country: Singapore
Release Id: 02082531601
You may like:
Amerigo Scientific Enhances Cell Culture Results by Introducing 3D Cell Culture Systems